Our Cancer Development & Progression program is focused on understanding mechanisms of cancer growth and progression. This program integrates basic and applied research in areas such as genomic integrity, tumor microenvironment, inflammation and hormone action. Our members provide important mechanistic insight into the process of tumorigenesis leading to new cancer prevention and treatment strategies, diagnostics and biomarkers of cancer. Interdisciplinary collaborations with members of the Experimental & Developmental Therapeutics program and the Cancer Prevention & Population Science program further develop discoveries from bench to bedside and back.
Our Experimental & Developmental Therapeutics program works to refine the way cancer is treated. This program’s activities span the range of experimental and developmental therapeutics from initial target discovery to regulatory approval for new treatments. The strength of the EDT program is the fostering of collaboration between pre-clinical and clinical researchers to develop novel therapies aimed at giving patients the best possible treatments. The CTRC’s Institute for Drug Development (IDD) specializes in the conduct of Phase I clinical trials using new anti-cancer drugs, and is integrated within the EDT program.
Our Cancer Prevention & Population Science program conducts collaborative, hypothesis- and evidence-based translational cancer prevention and control research. The CPPS program crosses the entire cancer continuum—primary prevention, early detection, laboratory research, clinical trials and applications, diagnosis and treatment, quality of life and survivorship. A major focus of the CPPS program is to reduce the Latino cancer burden, particularly in South Texas. To accomplish this, CPPS program members work closely with the UT Health Science Center San Antonio's Institute for Health Promotion Research (IHPR).The IHPR investigates the causes of and solutions to the unequal impact of cancer, chronic disease and obesity among Latinos in South Texas and beyond.